(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
J&J Begins Trial of Tip-Based Javelin IVL Catheter for Hard-to-Treat Arteries
Johnson & Johnson has launched a pivotal study of its Javelin intravascular lithotripsy (IVL) catheter, designed by Shockwave Medical to treat “difficult-to-cross” coronary arteries. Unlike balloon-based devices, Javelin emits sound pressure waves from its tip, allowing it to break up calcium deposits without needing to cross the blockage first—a key advantage in severely narrowed vessels.
The study will enroll up to 158 patients across 35 U.S. and U.K. sites to support coronary use approval. Javelin was previously cleared for peripheral vessels, expanding Shockwave’s reach in the IVL space.
J&J’s $13.1 billion acquisition of Shockwave and investment in balloon-free technology positions it against balloon-based rivals like Abbott and Boston Scientific. While Javelin targets only about 5% of the IVL market, it addresses a critical unmet need in complex coronary procedures.
23-04-2025
📰 Recent News
- Medtronic Seeks FDA Approval for Hugo Surgical Robot, Aiming to Challenge Intuitive
- FDA Warns ICU Medical Over Unapproved Changes to Infusion Pumps
- Medtronic Gains FDA Approval for World’s Smallest Defibrillation Lead, Omniasecure
- Abbott Links Glucose Monitoring Data with Epic’s Electronic Health Records
- Intuitive obtains new FDA nod for single port robot and Resmed buys diagnostic facility
- Ceribell wins FDA nod for algorithm to detect pediatric seizures
- Medtronic obtains FDA approval to utilise Simplera Sync glucose sensor integrated with insulin pumps
- Precision Neuroscience receives FDA clearance for brain implant
- FDA issues early alert for BD catheters due to leaks
- Medtronic seeks FDA approval for insulin pump, furthering Abbott collab